Citations

Clear

3042 citation(s) found for "Kumar, S".

Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Targeting the JAK-STAT pathway: Successful use of abrocitinib in refractory prurigo nodularis
De, Abhishek, Chakraborty, Disha, Ahmed, S. K. Shahriar, De, Abhishek , Singh, Arun Kumar , Chakraborty, Disha , Ahmed, S. K. Shahriar

Mayo Clinic

Indian Journal of Skin Allergy | March 20, 2026 | Volume: 5 | Issue: No issue available | Pages: 105-106

10.25259/ijsa_83_2025 Get It

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
Abdallah, Nadine, White, Thomas, Heeren, Amanda A., Wildes, Tanya, Marar, Rosalyn, Yee, Claire , Bodily, Anna, Kotajarvi, Brian R., Aug, Sarah, Kapoor, Prashant , Dispenzieri, Angela, Hayman, Suzanne, Dingli, David, Gonsalves, Wilson, Cook, Joselle, Zanwar, Saurabh , Lin, Y., Kourelis, Taxiarchis, Gertz, MA, Warsame, Rahma, Rajkumar, S, LeBrasseur, Nathan, Kumar, Shaji, Weivoda, Megan , Abdallah, Nadine H , Heeren, Amanda, Marar, Rosalyn , Yee, Claire , Kotajarvi, Brian, Buadi, Francis K , Kapoor, Prashant , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Gertz, Morie A , Rajkumar, S Vincent , Sfeir, Jad G , Kumar, Shaji K , Weivoda, Megan , Abdallah, Nadine , Smith, Byron H. , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Hayman, Suzanne, Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Sfeir, Jad , LeBrasseur, Nathan K

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8605152/v1 | PMID 41890848 Get It

Abstract Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.
Symptom Outcomes After Septal Perforation Surgical Repair Versus 3D ‐Printed Customized Prosthesis
Gomes, Pedro Lança , Kumar, Nitish, Bansberg, Stephen F. , Marino, Michael J. , Lal, Devyani, Miglani, Amar , Lal, Devyani , Kumar, Nitish , Kumar, Nitish , Lal, Devyani , Lança Gomes, Pedro

Mayo Clinic

The Laryngoscope | March 18, 2026 | Volume: 136 | Issue: 8 | Pages: 3452-3457

10.1002/lary.70508 | PMID 41844333 Get It

ABSTRACT Objective Surgical repair and 3D‐printed customized septal prosthesis (3D‐PCSP) are options for septal perforation treatment. We performed a study to compare the clinical outcomes of surgery and 3D‐PCSP using the NOSE‐Perf Scale (NPfS). Methods A chart review was performed on patients undergoing surgical repair or 3D‐PCSP placement between January 2018 and July 2024. The change in NPfS was used as primary endpoint. Demographics, ASA score, perforation size, etiology, and follow‐up duration were reported. Results Thirty‐five patients, 23 for surgical repairs and 12 for 3D‐PCSP, were included in this review [median (IQR)]. In the surgical repair group, perforation length and height measured 12 (10–18) mm and 10 (8–15) mm, respectively. Baseline NPfS was 24 (16–32), and this decreased to 8 (6–13) following surgical repair ( p < 0.001). Follow‐up time was 12 (5–21) months. In the 3D‐PCSP group, septal perforation length and height measured 25 (15–30) mm and 17 (15–20) mm, respectively. The baseline NPfS was 17 (3–24.5), and this decreased to 9.5 (7–13) following 3D‐PCSP placement ( p = 0.001). The follow‐up was 18.4 (16–23) months. NPfS reduction was greater for surgical repair ( p = 0.018). Conclusions Surgery and 3D‐PCSP offer meaningful symptom relief for NSP patients. Treatment decisions should be individualized through shared decision‐making that considers patient comorbidities, preferences, surgeon experience, and risk tolerance. In this cohort, surgical repair was associated with greater NPfS reduction compared with 3D‐PCSP placement. Level of Evidence 3.
Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Rasheed, Azgar Abdul , Ganguly, Shuvadeep, Singh, Manraj, Sreenivas, Vishnubhatla , Pillai, Ashwati S., Joison, Anu Theresa, Sharma, Swetambri , Bakhshi, Sameer , Singh, Manraj , Sra, Manraj Singh , Ganguly, Shuvadeep , Kumar, Santhosh E. , Batra, Atul , Pushpam, Deepam

Mayo Clinic

Pediatric Blood & Cancer | March 13, 2026 | Volume: 73 | Issue: 5 | Pages: No page available

10.1002/1545-5017.70171 | PMID 41823195 Get It

ABSTRACT Background Fosaprepitant is non‐inferior to aprepitant in adults receiving highly emetogenic chemotherapy (HEC). We evaluated whether fosaprepitant is non‐inferior to aprepitant in children receiving HEC. Methods In this open‐label, non‐inferiority trial, children aged 5–18 years, receiving their first cycle of HEC, were randomized 1:1 to the fosaprepitant or aprepitant group. The fosaprepitant group received a single intravenous dose of 4 mg/kg (max 150 mg). The aprepitant group received oral aprepitant capsules (weight 15 to <30 kg: 80 mg Days 1–3; weight ≥30 kg, or age ≥12 years: 125 mg Day 1, 80 mg Days 2 and 3). Both groups received ondansetron and dexamethasone. The primary outcome was the complete response (CR) rate of vomiting during the acute phase (AP) with a non‐inferiority margin of 15%. Secondary outcomes included CR rates in the delayed (DP) and overall phases (OP), grade of vomiting, incidence and severity of nausea, and adverse effects. Results A total of 279 children were included in the modified intention‐to‐treat analysis (fosaprepitant group: 140; aprepitant group: 139). In AP, the difference of CR rate between fosaprepitant [76 (54.3%)] and aprepitant groups [84 (60.4%)] was −6.1% [90% CI: −15.7% to +3.6%], with the lower limit exceeding −15%, failing to establish non‐inferiority. The CR rate with fosaprepitant versus aprepitant was 62.1% ( n = 87) versus 65.5% ( n = 91) in DP (difference: –3.4%; 90% CI: –12.7% to 6.1%) and 42.9% ( n = 60) versus 49.6% ( n = 69) in the OP (difference: –6.7%; 90% CI: –16.5% to 3.1%). Grade of vomiting, incidence and severity of nausea, and adverse effects were similar between the two groups. Conclusions Non‐inferiority of fosaprepitant compared to aprepitant was not demonstrated in children undergoing their first cycle of HEC. Trial Registration Clinical Trials Registry, India (CTRI/2019/05/019082).
ULK4 and CDKN2A polymorphisms influence the risk of developing monoclona
Macauda, A., Cabrera-Serrano, Antonio José , Thomsen, Hauke, Güler, Murat, Guelpen, Bethany Van , Landi, S., Chattopadhyay, Subhayan , Unal, P., Ruiz‐Durán, Lucía, Casabonne, Delphine , Goldschmidt, Hartmut, Carretero‐Fernández, María, Cabezudo, Elena Duque, Norman, A., García‐Sánz, Ramón , Pettersson‐Kymmer, Ulrika, Jiménez‐Romera, Francisco, Rajkumar, S. Vincent, Weinhold, Niels , Vodickova, Ludmila, Langer, C., Stein, Angelika, Karismaz, Abdulkadir, Jöckel, K‐H, Martínez‐López, Joaquín, Kumar, Shaji K., Gutiérrez‐Bautista, Juan Francisco , Basso, Daniela, Späth, Florentin , Benavente, Yolanda , Hildebrandt, Michelle A. T., Schmidt, Börge, Reis, Rui Manuel , Li, Yang, Netea, M. G. , Campa, Daniele, Clay‐Gilmour, Alyssa, Hemminki, Kari, Vachon, Celine M, Martínez‐López, Joaquín , Landi, Stefano , Thomsen, Hauke , Van Guelpen, Bethany , Landi, Stefano , Casabonne, Delphine , Moreno, Victor , Tavano, Francesca , Hildebrandt, Michelle A T , Schmidt, Börge , Reis, Rui Manuel , Campa, Daniele , Försti, Asta , Canzian, Federico , Sainz, Juan , Garcia-Sanz, Ramon , Martinez-Lopez, Joaquin , Thomsen, Hauke , Carretero-Fernández, María , Sánchez‐Maldonado, José Manuel , Macauda, Angelica , Horst, Rob ter , Vodička, Pavel , Ruiz-Durán, Lucía , Goldschmidt, Hartmut , Serin, İstemi , Reyes‐Zurita, Fernando J. , Norman, Aaron D. , Capurso, Gabriele , Hoffmann, Per , Petterson-Kymmer, Ulrika, Jiménez-Romera, Francisco, Rajkumar, S. Vincent , Vodičková, Ľudmila , Karışmaz, Abdülkadir , Moreno, Vı́ctor , Nöthen, Markus M. , Tavano, Francesca , Kumar, Shaji , Basso, Daniela , Hildebrandt, Michelle A.T. , Ševčíková, Tereza , López‐Nevot, Miguel Ángel , Clay‐Gilmour, Alyssa , Slager, Susan L. , Hemminki, Kari, Försti, Asta , Canzian, Federico , Sáinz, Juan

Mayo Clinic

International Journal of Cancer | March 12, 2026 | Volume: 159 | Issue: 2 | Pages: 410-422

10.1002/ijc.70427 | PMID 41813586 Get It

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is a necessary precursor condition to multiple myeloma (MM). Given the role of autophagy in modulating MM risk, we investigated whether genetic variation in autophagy‐related genes influences susceptibility to MGUS. We analyzed the association of 34,042 common autophagy‐related single nucleotide polymorphisms (SNPs) with MGUS across six independent cohorts, five from Europe and one from North America, comprising 2317 MGUS cases and 282,358 controls. We also assessed their impact on immune parameters, including absolute counts of 91 blood‐derived immune cell subsets and 103 circulating immunological proteins. Meta‐analysis revealed a genome‐wide significant association between the ULK4 rs6599175C allele and increased MGUS risk ( p = 3.35 × 10 −8 ). Carriers of this allele showed reduced counts of memory B cell subsets (IgM+CD38+CD27+ and IgD+IgM+CD27+; p = .0038 and p = .0056, respectively) and natural effector B cells (CD24+CD38+IgD+IgM+ cells; p = .0060). Although these associations were not statistically significant after multiple testing correction, they suggest a role of ULK4 in early B‐cell differentiation. Additionally, the CDKN2A rs2811710 variant showed a suggestive association with MGUS risk ( p = 2.17 × 10 −4 ), affecting transcription factor binding involved in B‐cell proliferation and differentiation, although it lacked association with immune markers. In conclusion, we confirm a genome‐wide significant association of the ULK4 locus and MGUS risk, supporting its role in early B‐cell differentiation, and identify CDKN2A as a candidate susceptibility locus warranting further investigation.
Direct detection and quantification of Mycobacterium tuberculosis from clinical samples by high-resolution melt qPCR
Babu, Aishwarya S. , Yadav, Priyanka , Ponnusamy, P. , Govindaraj, Vishnukanth , Kumar, Saka Vinod , Pandey, Akhilesh , Verma, Renu , Pandey, Akhilesh , Ellappan, Kalaiarasan , Joseph, Noyal Mariya

Mayo Clinic

No container title available | March 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.07.26347851 Get It

Abstract Background Estimating bacterial load in clinical samples has important applications in tuberculosis (TB) management, including assessment of disease severity, treatment response, and baseline genome copies required for sequencing. However, rapid and affordable tools for quantifying Mycobacterium tuberculosis ( M. tuberculosis ) remain limited. Methods We developed a high-resolution melt (HRM) based quantitative PCR assay using molecular beacon chemistry targeting the single-copy RD9 region of M. tuberculosis . Analytical performance was assessed using 10-fold serial dilutions of H37Rv DNA. Clinical validation included DNA from 100 M. tuberculosis culture isolates and 40 sputum samples from Xpert MTB/RIF- and culture-positive pulmonary TB patients. To evaluate specificity, we tested 30 non-tuberculous mycobacterium (NTM) culture isolates from patients infected with Mycobacterium abscessus (n=25) and Mycobacterium fortuitum (n=5) and DNA from saliva samples of 10 healthy controls. Results The HRM-qPCR assay showed a linear dynamic range from 10 1 to 10 6 genome copies per reaction, with a lower limit of detection of 10 copies. Standardized melt-curve analysis yielded a single target-specific peak at 73.7±0.12°C across dilutions, confirming specific amplification. Sensitivity for M. tuberculosis detection was 100% in culture isolates and 95.0% (38/40) in sputum, with no false positives among M. tuberculosis -negative controls. Assay specificity was 100% in both culture isolates and sputum, with no additional melt peaks. We did not observe any peaks indicative of non-specific binding in NTMs. Amplification was observed in two NTM samples whose Tm matched M. tuberculosis RD9 (median M. tuberculosis copies=678.5), suggesting possible co-infection or contamination. No amplification or specific melt peaks were observed in saliva samples, indicating high probe specificity. Conclusions Molecular beacon-based HRM-qPCR assay enables rapid, highly specific quantification of M. tuberculosis genome copies in clinical samples and has potential utility for treatment monitoring, triaging specimens for sequencing, and assessing transmission risk in high-burden settings.
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement
D’Angelo, Christopher R., Godara, Amandeep , Lee, Hans C., Kumar, Shaji, D’Angelo, Christopher R. , Derman, Benjamin A. , Devarakonda, Srinivas , Lee, Hans C. , Robinson, Timothy, Kumar, Shaji , Callander, Natalie S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 9, 2026 | Volume: 24 | Issue: 5 | Pages: No page available

10.6004/jnccn.2025.7105 | PMID 41825121 Get It

Extramedullary presentations of multiple myeloma (MM) involving the central nervous system (CNS) carry a dismal prognosis. Although historically rare, management of extramedullary disease—including CNS manifestations—has become increasingly clinically relevant as advances in systemic therapies have prolonged control of medullary disease. CNS manifestations may occur across a variety of clinical settings and at different time points throughout the disease course. Common symptoms include visual changes, headaches, loss of sensation, confusion, and seizures. MRI identifies leptomeningeal enhancement and/or parenchymal lesions in approximately 90% of cases, and lumbar puncture with cerebrospinal fluid testing for clonal plasma cell populations is confirmatory. Encouragingly, the incorporation of novel therapeutic agents has improved historically poor outcomes in CNS MM. Novel immunotherapeutic approaches using CAR T-cell therapy and bispecific T-cell–engaging antibodies have recently demonstrated significant efficacy in consolidating responses. Multimodality treatment strategies incorporating intrathecal chemotherapy, systemic novel agents, radiation therapy, and immunotherapy hold promise for achieving more durable responses in this devastating manifestation of MM.
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients
Mellgard, George , Bazarbachi, Abdul-Hamid, Zanwar, Saurabh , Hegenbart, Ute , Bodanapu, Geethika , Bhutani, Divaya , Chen, G., D'Souza, A, Dispenzieri, Angela, Gertz, Morie, Kumar, Shaji, Lentzsch, Suzanne , Milani, Paolo, Muchtar, E., Palladini, Giovanni, Trajanova, Despina, Patwari, Anannya , Sanchorawala, Vaishali, Mohty, Mohamad, Wang, Shikun , Kastritis, Efstathios, Theodorakakou, Foteini, Cowan, Andrew J, Gertz, Morie A. , D’Souza, Anita , D'Souza, Anita , Gertz, Morie A , Palladini, Giovanni , Sanchorawala, Vaishali , Kastritis, Efstathios , Theodorakakou, Foteini , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Bazarbachi, Abdul Hamid , Dispenzieri, Angela , Milani, Paolo , Muchtar, Eli , Mohty, Mohamad , Kastritis, Efstathios , Theodorakakou, Foteini , Schönland, Stefan , Chakraborty, Rajshekhar

Mayo Clinic

American Journal of Hematology | March 8, 2026 | Volume: 101 | Issue: 4 | Pages: 768-783

10.1002/ajh.70257 | PMID 41793153 Get It

ABSTRACT Systemic AL amyloidosis is a clonal plasma cell dyscrasia, where toxic free light chains (FLCs) lead to vital organ damage, with risk of early mortality despite effective therapies. Notably, there is a paucity of data on the incidence and predictors of early mortality in the daratumumab (Dara) era. We conducted a multi‐center retrospective cohort study to develop and validate a risk‐prediction model for early mortality (all‐cause death within 6 months) in patients treated with Dara‐based frontline regimens. We used univariate analysis to identify covariates for a logistic regression model predictive of 6‐month mortality and generated a clinical risk score. Among 339 patients across eight centers, 36 (10.6%) experienced early mortality. Multivariate analysis identified four independent predictors: NT‐proBN P > 5300 pg/mL (odds ratio [OR] 3.83, p = 0.006), A ge > 75 years (OR 2.96, p = 0.073), absence of t(11;14) on C ytogenetics (OR 3.0, p = 0.022), and E COG performance status (OR 1.72 per unit increase, p = 0.044). The resulting PACE score stratified patients into three risk groups with a 6‐month mortality of 1.2% (low‐risk), 11.7% (intermediate‐risk), and 50.0% (high‐risk). The PACE score demonstrated superior discrimination (C‐index 0.78) for early mortality compared to Mayo 2004 (0.69) and Mayo 2012 (0.55) staging systems. External validation confirmed robust discrimination (C‐index 0.73) with corresponding 6‐month mortality rates of 4.2%, 15.25%, and 37.04% across respective risk groups. The PACE score provides a clinically applicable tool for early mortality risk stratification in AL amyloidosis patients receiving Dara‐based therapy, and will enable improved patient counseling, clinical trial design, and identification of ultra‐high‐risk patients requiring intensive monitoring and novel therapies.